Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Observational Study of the Impact of Efanesoctocog Alfa (ALTUVIIIO) on Goal Attainment and Physical Activity in People With Moderate or Severe Hemophilia A

Next Previous
Trial Profile

Prospective, Observational Study of the Impact of Efanesoctocog Alfa (ALTUVIIIO) on Goal Attainment and Physical Activity in People With Moderate or Severe Hemophilia A

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efanesoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms ACTIVIIITY
  • Sponsors Sanofi

Most Recent Events

  • 20 Jan 2026 Status changed from recruiting to discontinued.
  • 03 Feb 2025 Planned End Date changed from 20 Jul 2026 to 31 Aug 2026.
  • 03 Feb 2025 Planned primary completion date changed from 10 Apr 2026 to 31 Aug 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top